Updated on 29 September 2026
Strategic Investment Opportunity in Advanced Biotechnoly and Biomedical Systems
Head of Research at Omnia Mater SL
Madrid, Spain
About
We are a consortium of three specialized biotech and biomedical SMEs (Silk Biomed, Bioactive Surfaces, Omnia Mater) leading a robust portfolio of high-impact national and European projects, including EIC Pathfinders. Our multidisciplinary expertise drives the development of next-generation medical technologies across varying maturity levels, from TRL 3/4 to commercially available products.
Our diverse innovation pipeline includes:
-
Regenerative Bioprinting: An advanced 3D cell bioprinter alongside Spider-THOR, a bioinspired system featuring up to six micro-robotic arms with 1.0 μm precision for in-situ brain and spinal cord bioprinting.
-
Precision Diagnostics: High-fidelity Organs-on-chip, including a specialized Retina-on-chip platform for Age-Related Macular Degeneration (AMD) research and drug testing.
-
Advanced Materials: Functionalization of inorganic surfaces for high-performance dental implants and the development of Engineered Living Materials (ELMs).
-
Clinical Integration: Systems designed for intraoperative use that trigger rapid angiogenesis and minimize glial scarring by matching the brain’s extreme structural softness.
We are seeking strategic partners and investors to accelerate the scaling of our commercial products and the clinical translation of our deep-tech biomedical portfolio.
Similar opportunities
Expertise
Advanced Bioprinting and Biofabrication Systems
Gianna Arencibia
Head of Research at Omnia Mater SL
Madrid, Spain
Investment
THOR-X: Compact High-Precision Bioprinting for Next-Generation Tissue Engineering
Gianna Arencibia
Head of Research at Omnia Mater SL
Madrid, Spain